Troels Staehelin Jensen

Troels Staehelin Jensen

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Troels Staehelin Jensen

Danish Pain Research Center, Department of Clinical Medicine Aarhus University Aarhus N Denmark

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
NFNanna Brix Finnerup
Nanna Brix Finnerup
RKRohini Kuner
Rohini Kuner
TJTroels Staehelin Jensen
Troels Staehelin Jensen
Neuropathic pain caused by a lesion or disease of the somatosensory nervous system is a common chronic pain condition with major impact on quality of life. Examples include trigeminal neuralgia, painful polyneuropathy, postherpetic neuralgia, and central poststroke pain. Most patients complain of an ongoing or intermittent spontaneous pain of, for example, burning, pricking, squeezing quality, which may be accompanied by evoked pain, particular to light touch and cold. Ectopic activity in, for example, nerve-end neuroma, compressed nerves or nerve roots, dorsal root ganglia, and the thalamus may in different conditions underlie the spontaneous pain. Evoked pain may spread to neighboring areas, and the underlying pathophysiology involves peripheral and central sensitization. Maladaptive structural changes and a number of cell-cell interactions and molecular signaling underlie the sensitization of nociceptive pathways. These include alteration in ion channels, activation of immune cells, glial-derived mediators, and epigenetic regulation. The major classes of therapeutics include drugs acting on α2δ subunits of calcium channels, sodium channels, and descending modulatory inhibitory pathways.

1 September 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
TJTroels S Jensen
Troels S Jensen
NFNanna Brix Finnerup
Nanna Brix Finnerup

12 March 2019 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
LBL. Bendtsen
L. Bendtsen
JZJ. M. Zakrzewska
J. M. Zakrzewska
JAJ. Abbott
J. Abbott
MBM. Braschinsky
M. Braschinsky
GSGiulia Di Stefano
Giulia Di Stefano
GCG. Cruccu
G. Cruccu
Background and purpose: Trigeminal neuralgia (TN) is an extremely painful condition which can be difficult to diagnose and treat. In Europe, TN patients are managed by many different specialities. Therefore, there is a great need for comprehensive European guidelines for the management of TN. The European Academy of Neurology asked an expert panel to develop recommendations for a series of questions that are essential for daily clinical management of patients with TN.Methods: A systematic review of the literature was performed and recommendations was developed based on GRADE, where feasible; if not, a good practice statement was given.Results: The use of the most recent classification system is recommended, which diagnoses TN as primary TN, either classical or idiopathic depending on the degree of neurovascular contact, or as secondary TN caused by pathology other than neurovascular contact. Magnetic resonance imaging (MRI), using a combination of three high‐resolution sequences, should be performed as part of the work‐up in TN patients, because no clinical characteristics can exclude secondary TN. If MRI is not possible, trigeminal reflexes can be used. Neurovascular contact plays an important role in primary TN, but demonstration of a neurovascular contact should not be used to confirm the diagnosis of TN. Rather, it may help to decide if and when a patient should be referred for microvascular decompression. In acute exacerbations of pain, intravenous infusion of fosphenytoin or lidocaine can be used. For long‐term treatment, carbamazepine or oxcarbazepine are recommended as drugs of first choice. Lamotrigine, gabapentin, botulinum toxin type A, pregabalin, baclofen and phenytoin may be used either alone or as add‐on therapy. It is recommended that patients should be offered surgery if pain is not sufficiently controlled medically or if medical treatment is poorly tolerated. Microvascular decompression is recommended as first‐line surgery in patients with classical TN. No recommendation can be given for choice between any neuroablative treatments or between them and microvascular decompression in patients with idiopathic TN. Neuroablative treatments should be the preferred choice if MRI does not demonstrate any neurovascular contact. Treatment for patients with secondary TN should in general follow the same principles as for primary TN. In addition to medical and surgical management, it is recommended that patients are offered psychological and nursing support.Conclusions: Compared with previous TN guidelines, there are important changes regarding diagnosis and imaging. These allow better characterization of patients and help in decision making regarding the planning of medical and surgical management. Recommendations on pharmacological and surgical management have been updated. There is a great need for future research on all aspects of TN, including pathophysiology and management.

1 November 2017 in The Lancet Neurology
Verified
Journal Article
Closed access
ATAstrid Juhl Terkelsen
Astrid Juhl Terkelsen
PKPáll Karlsson
Páll Karlsson
GLGiuseppe Lauria
Giuseppe Lauria
RFRoy Freeman
Roy Freeman
NFNanna Brix Finnerup
Nanna Brix Finnerup
TJTroels S Jensen
Troels S Jensen

12 March 2021 in Brain
Verified
Journal Article
Open access
PDF file
TJTroels S Jensen
Troels S Jensen
PKPall Karlsson
Pall Karlsson
SGSandra S Gylfadottir
Sandra S Gylfadottir
SASigne T Andersen
Signe T Andersen
DBDavid L Bennett
David L Bennett
BCBrian C Callaghan
Brian C Callaghan
Peripheral neuropathy is one of the most common complications of both type 1 and type 2 diabetes. Up to half of patients with diabetes develop neuropathy during the course of their disease, which is accompanied by neuropathic pain in 30–40% of cases. Peripheral nerve injury in diabetes can manifest as progressive distal symmetric polyneuropathy, autonomic neuropathy, radiculo-plexopathies, and mononeuropathies. The most common diabetic neuropathy is distal symmetric polyneuropathy, which we will refer to as DN, with its characteristic glove and stocking like presentation of distal sensory or motor function loss. DN or its painful counterpart, painful DN, are associated with increased mortality and morbidity; thus, early recognition and preventive measures are essential. Nevertheless, it is not easy to diagnose DN or painful DN, particularly in patients with early and mild neuropathy, and there is currently no single established diagnostic gold standard. The most common diagnostic approach in research is a hierarchical system, which combines symptoms, signs, and a series of confirmatory tests. The general lack of long-term prospective studies has limited the evaluation of the sensitivity and specificity of new morphometric and neurophysiological techniques. Thus, the best paradigm for screening DN and painful DN both in research and in clinical practice remains uncertain. Herein, we review the diagnostic challenges from both clinical and research perspectives and their implications for managing patients with DN. There is no established DN treatment, apart from improved glycaemic control, which is more effective in type 1 than in type 2 diabetes, and only symptomatic management is available for painful DN. Currently, less than one-third of patients with painful DN derive sufficient pain relief with existing pharmacotherapies. A more precise and distinct sensory profile from patients with DN and painful DN may help identify responsive patients to one treatment versus another. Detailed sensory profiles will lead to tailored treatment for patient subgroups with painful DN by matching to novel or established DN pathomechanisms and also for improved clinical trials stratification. Large randomized clinical trials are needed to identify the interventions, i.e. pharmacological, physical, cognitive, educational, etc., which lead to the best therapeutic outcomes.

5 December 2024 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
Masha SavelieffMasha Savelieff
Masha Savelieff
MEMelissa A. Elafros
Melissa A. Elafros
VVVijay Viswanathan
Vijay Viswanathan
TJTroels S. Jensen
Troels S. Jensen
DBDavid L. Bennett
David L. Bennett
EFEva L. Feldman
Eva L. Feldman